Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 13 | 2023 | 2142 | 2.490 |
Why?
|
| Heart Transplantation | 7 | 2021 | 713 | 2.300 |
Why?
|
| Heart-Assist Devices | 4 | 2021 | 529 | 1.620 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 311 | 1.090 |
Why?
|
| Patient Selection | 2 | 2020 | 671 | 1.020 |
Why?
|
| Cardiology | 2 | 2020 | 281 | 1.010 |
Why?
|
| Registries | 4 | 2019 | 1916 | 0.780 |
Why?
|
| Stroke Volume | 3 | 2020 | 587 | 0.740 |
Why?
|
| Hospice Care | 1 | 2023 | 197 | 0.700 |
Why?
|
| Home Care Services | 1 | 2023 | 246 | 0.690 |
Why?
|
| Medicare | 2 | 2023 | 734 | 0.690 |
Why?
|
| Waiting Lists | 2 | 2019 | 242 | 0.680 |
Why?
|
| BK Virus | 1 | 2019 | 14 | 0.670 |
Why?
|
| Population Health | 1 | 2020 | 46 | 0.660 |
Why?
|
| Immunocompromised Host | 2 | 2020 | 198 | 0.630 |
Why?
|
| Patient Advocacy | 1 | 2019 | 73 | 0.630 |
Why?
|
| Viremia | 1 | 2019 | 133 | 0.620 |
Why?
|
| Triage | 1 | 2020 | 211 | 0.580 |
Why?
|
| Renal Insufficiency | 1 | 2019 | 150 | 0.570 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2018 | 82 | 0.560 |
Why?
|
| Organizational Objectives | 1 | 2017 | 73 | 0.560 |
Why?
|
| Health Policy | 1 | 2020 | 359 | 0.550 |
Why?
|
| Betacoronavirus | 1 | 2020 | 266 | 0.550 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 102 | 0.550 |
Why?
|
| Pacemaker, Artificial | 1 | 2018 | 115 | 0.530 |
Why?
|
| Heart Diseases | 1 | 2020 | 356 | 0.530 |
Why?
|
| Cardiovascular System | 1 | 2017 | 138 | 0.510 |
Why?
|
| Mentors | 1 | 2017 | 174 | 0.500 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 896 | 0.500 |
Why?
|
| Mentoring | 1 | 2017 | 120 | 0.480 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 421 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 361 | 0.470 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 355 | 0.470 |
Why?
|
| Health Services Research | 1 | 2017 | 392 | 0.460 |
Why?
|
| Quality Improvement | 2 | 2020 | 1101 | 0.410 |
Why?
|
| Medication Adherence | 1 | 2016 | 571 | 0.370 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 295 | 0.370 |
Why?
|
| Biomedical Research | 1 | 2017 | 654 | 0.360 |
Why?
|
| United States | 7 | 2023 | 13975 | 0.290 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2019 | 101 | 0.280 |
Why?
|
| Humans | 20 | 2023 | 128896 | 0.260 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 7050 | 0.220 |
Why?
|
| Female | 12 | 2023 | 68162 | 0.200 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1281 | 0.190 |
Why?
|
| Insurance, Health | 2 | 2021 | 269 | 0.180 |
Why?
|
| Male | 11 | 2023 | 63146 | 0.180 |
Why?
|
| Pericarditis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Cryptococcus neoformans | 1 | 2020 | 20 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2767 | 0.170 |
Why?
|
| Cryptococcosis | 1 | 2020 | 26 | 0.170 |
Why?
|
| Hospitalization | 2 | 2023 | 2080 | 0.170 |
Why?
|
| Aged | 7 | 2023 | 22035 | 0.170 |
Why?
|
| Cardiologists | 1 | 2020 | 46 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 4917 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2020 | 10239 | 0.160 |
Why?
|
| Risk Assessment | 2 | 2020 | 3286 | 0.150 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 128 | 0.150 |
Why?
|
| Risk Factors | 2 | 2023 | 9792 | 0.150 |
Why?
|
| Adult | 7 | 2020 | 35361 | 0.150 |
Why?
|
| Retrospective Studies | 3 | 2023 | 14546 | 0.150 |
Why?
|
| Viral Load | 1 | 2019 | 448 | 0.140 |
Why?
|
| Community Health Services | 1 | 2019 | 224 | 0.140 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 74 | 0.140 |
Why?
|
| Long-Term Care | 1 | 2018 | 88 | 0.140 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 42 | 0.140 |
Why?
|
| Patient Safety | 1 | 2020 | 292 | 0.140 |
Why?
|
| Professional Competence | 1 | 2017 | 94 | 0.130 |
Why?
|
| Patient Participation | 1 | 2020 | 402 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2018 | 5394 | 0.130 |
Why?
|
| Stakeholder Participation | 1 | 2017 | 76 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 189 | 0.130 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 15 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 570 | 0.130 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2016 | 46 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1435 | 0.120 |
Why?
|
| Career Choice | 1 | 2017 | 211 | 0.120 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 272 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 207 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2016 | 246 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 615 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2014 | 44 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2017 | 404 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 708 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 236 | 0.110 |
Why?
|
| Survival Rate | 1 | 2018 | 1884 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1213 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1282 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 1090 | 0.100 |
Why?
|
| Medicaid | 1 | 2017 | 445 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 504 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1516 | 0.090 |
Why?
|
| Curriculum | 1 | 2017 | 925 | 0.090 |
Why?
|
| Logistic Models | 1 | 2016 | 1963 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1504 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 3133 | 0.090 |
Why?
|
| Time Factors | 2 | 2016 | 6568 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2019 | 2494 | 0.070 |
Why?
|
| Middle Aged | 5 | 2020 | 30977 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 5355 | 0.060 |
Why?
|
| Pericardiocentesis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Fluconazole | 1 | 2020 | 18 | 0.040 |
Why?
|
| Health Services Misuse | 1 | 2020 | 36 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 132 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 634 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2020 | 225 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 387 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2017 | 127 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 537 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 101 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2017 | 220 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1366 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1715 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 817 | 0.030 |
Why?
|
| Acute Disease | 1 | 2015 | 978 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 619 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 859 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 694 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 3787 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 3874 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 7060 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 12286 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 20197 | 0.010 |
Why?
|